All In Biotech

Drug Trial Radar · NCT04318938

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Mar 30, 2020

Primary completion

May 30, 2026

Study completion May 30, 2026

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Thoraxklinik-Heidelberg gGmbH; Takeda
First posted
Mar 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Conditions

  • NSCLC

Interventions

  • BrigatinibDrug

    Treatment with Brigatinib

  • Tyrosine kinase inhibitorDrug

    Treatment with any TKI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) of 1st-line treatment according to RECIST v1.1Time frame: 68 months

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • HELIOS Klinikum Emil von Behring

    Berlin, Germany

  • Charité Berlin

    Berlin, Germany

  • Lungenklinik Köln - Merheim

    Cologne, Germany

  • Universitätsmedizin Essen

    Essen, Germany

  • Klinikum Esslingen

    Esslingen am Neckar, Germany

  • Krankenhaus Nordwest Frankfurt

    Frankfurt am Main, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Niels-Stensen-Kliniken Georgsmarienhütte

    Georgsmarienhütte, Germany

  • Universitätsklinikum Gießen

    Giessen, Germany

  • Studiengesellschaft Hämato-Onkologie Hamburg

    Hamburg, Germany

  • Evangelisches Krankenhaus Hamm

    Hamm, Germany

  • KRH Klinikum Siloah Hannover

    Hanover, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Thoraxklinik am Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Lungenklinik Hemer

    Hemer, Germany

  • Universitätsklinikum Jena

    Jena, Germany

  • Universitätsklinikum Leipzig

    Leipzig, Germany

  • Universitätsmedizin Mainz

    Mainz, Germany

  • Klinik der LMU München - Innenstadt

    München, Germany

  • Universitätsklinikum Münster

    Münster, Germany

  • Klinikum Nürnberg

    Nuremberg, Germany

  • Pius Hospital Oldenburg

    Oldenburg, Germany

  • Universitätsklinikum Regensburg

    Regensburg, Germany

  • Klinik Schillerhöhe

    Stuttgart, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.